142 related articles for article (PubMed ID: 14510733)
1. Safety of rofecoxib in nonsteroidal anti-inflammatory drugs intolerance.
Muñoz-Bellido FJ; Terrón M; León A
Allergy; 2003 Oct; 58(10):1072-5. PubMed ID: 14510733
[No Abstract] [Full Text] [Related]
2. Probable rofecoxib-induced thrombocytopenia.
Kentos A; Robin V; Lambermont M; Jurdan M; Pignarelli M; Feremans W
Rheumatology (Oxford); 2003 May; 42(5):699-700. PubMed ID: 12709555
[No Abstract] [Full Text] [Related]
3. Selective cyclooxygenase-2 inhibitors: a pattern of nephrotoxicity similar to traditional nonsteroidal anti-inflammatory drugs.
Perazella MA; Tray K
Am J Med; 2001 Jul; 111(1):64-7. PubMed ID: 11448662
[No Abstract] [Full Text] [Related]
4. Central retinal vein occlusion in a patient with rheumatoid arthritis taking rofecoxib.
Meyer Ch; Gähler R
Lancet; 2002 Oct; 360(9339):1100. PubMed ID: 12384019
[No Abstract] [Full Text] [Related]
5. The perioperative use of cyclooxygenase-2 selective nonsteroidal antiinflammatory drugs may offer a safer alternative.
Reuben SS; Connelly NR
Anesthesiology; 2004 Mar; 100(3):748. PubMed ID: 15109000
[No Abstract] [Full Text] [Related]
6. [No loss of effectiveness with rofecoxib. Long-term control of rheumatoid pain].
Einecke D
MMW Fortschr Med; 2002 Nov; 144(46):68. PubMed ID: 12534087
[No Abstract] [Full Text] [Related]
7. Factor-sparing use of the COX-2 inhibitor rofecoxib in haemophilic arthropathy.
Bragadóttir G; Onundarson PT
Haemophilia; 2002 Nov; 8(6):832-3. PubMed ID: 12410658
[No Abstract] [Full Text] [Related]
8. [Specific inhibitors of cyclooxygenase type 2] ].
Tomasová-Studýnková J
Vnitr Lek; 2002 May; 48(5):403-8. PubMed ID: 12061207
[TBL] [Abstract][Full Text] [Related]
9. Acute urinary retention associated with the use of cyclooxygenase-2 inhibitors.
Gruenenfelder J; McGuire EJ; Faerber GJ
J Urol; 2002 Sep; 168(3):1106. PubMed ID: 12187239
[No Abstract] [Full Text] [Related]
10. The new COX-2 inhibitors: rofecoxib (Vioxx) and celecoxib (Celebrex).
Wynn RL
Gen Dent; 2000; 48(1):16-20. PubMed ID: 11199547
[No Abstract] [Full Text] [Related]
11. Cardiovascular events and COX-2 inhibitors.
Fleming M
JAMA; 2001 Dec; 286(22):2808; author reply 2811-2. PubMed ID: 11735742
[No Abstract] [Full Text] [Related]
12. Anaphylactoid reaction to a cyclooxygenase-2 inhibitor in a patient who had a reaction to a cyclooxygenase-1 inhibitor.
Schellenberg RR; Isserow SH
N Engl J Med; 2001 Dec; 345(25):1856. PubMed ID: 11752370
[No Abstract] [Full Text] [Related]
13. COX-2-specific inhibition: implications for clinical practice.
Pascucci RA
J Am Osteopath Assoc; 1999 Nov; 99(11 Suppl):S18-22. PubMed ID: 10643177
[TBL] [Abstract][Full Text] [Related]
14. The coxibs, selective inhibitors of cyclooxygenase-2.
Killen JP
N Engl J Med; 2001 Dec; 345(23):1708; author reply 1709. PubMed ID: 11759656
[No Abstract] [Full Text] [Related]
15. COX-2 selective non-steroidal anti-inflammatory drugs and cardiovascular disease.
Ray WA; MacDonald TM; Solomon DH; Graham DJ; Avorn J
Pharmacoepidemiol Drug Saf; 2003; 12(1):67-70. PubMed ID: 12616850
[No Abstract] [Full Text] [Related]
16. [COX-2 inhibitor in arthrosis. Discontinuation before operations not necessary].
MMW Fortschr Med; 2001 Oct; 143(42):64. PubMed ID: 11697296
[No Abstract] [Full Text] [Related]
17. Why do COX-2 inhibitors increase risk of cardiovascular events?
Frankish H
Lancet; 2002 Apr; 359(9315):1410. PubMed ID: 11978344
[No Abstract] [Full Text] [Related]
18. COX-2 inhibitors: better than traditional NSAIDs? Vioxx and Celebrex may be no less risky than NSAIDs.
Atkinson HG
Health News; 2002 Aug; 8(8):5. PubMed ID: 12206146
[No Abstract] [Full Text] [Related]
19. Acute interstitial nephritis and COX-2 inhibition.
Chow KM; Szeto CC; Li P; Lai FM
Hosp Med; 2003 Jul; 64(7):429. PubMed ID: 12886856
[No Abstract] [Full Text] [Related]
20. [COX-2 specific inhibitors: are NSAIDs and the stomach become reconcilied?].
Bannwarth B
Gastroenterol Clin Biol; 2001 Apr; 25(4 Suppl):B79-84. PubMed ID: 11449148
[No Abstract] [Full Text] [Related]
[Next] [New Search]
